Business / Finance RSS Feed - Business / Finance

Henry Schein invests in Iwase Dental Supply

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it has invested in Iwase Dental Supply, Inc., a leading full-service provider of dental consumables, implants and equipment in Japan. [More]

Altamont announces majority equity investment in Legacy ER & Urgent Care

Altamont Capital Partners (Altamont) and Kingfish Group (Kingfish) today announced a majority equity investment into Legacy ER & Urgent Care (Legacy), a leading operator of hybrid standalone ER and urgent care clinics. [More]

SynGen announces relocation of corporate headquarters

SynGen, Inc., a company focused on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has moved its corporate headquarters to a new location in Sacramento, California. The headquarter’s new address is 100 Howe Avenue, Suite 185N, Sacramento, CA 95825-8219. All other contact information, including phone numbers, remains the same. [More]
Emo Capital, I-Omni partner to develop new compression wear clothing line

Emo Capital, I-Omni partner to develop new compression wear clothing line

Emo Capital Corp. is pleased to announce that a memorandum of understanding (MOU) was signed with I-Omni Co. Ltd. of Seoul, South Korea . [More]
Highland completes US$25 million offering of Class A Common Shares

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success. [More]

Danaher's net earnings increase 13% to $680.6 million in third quarter 2014

Danaher Corporation today announced results for the third quarter of 2014. [More]
Amedica, Spinal Kinetics sign strategic agreement for silicon nitride spinal interbody fusion devices

Amedica, Spinal Kinetics sign strategic agreement for silicon nitride spinal interbody fusion devices

Amedica Corporation, a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopaedic implants, is pleased to announce that it has entered into a multi-year private labeling agreement with Spinal Kinetics, a leading innovator of advanced artificial spinal disc technology. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Carpal Aid, Yew Bio-Pharm ink exclusive distribution deal

Carpal Aid, Yew Bio-Pharm ink exclusive distribution deal

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China, today announced a multi-year exclusive distribution agreement with Carpal Aid to distribute its non-invasive medical device "Carpal Aid" for carpal tunnel syndrome throughout China. [More]
GenCell Biosystems acquired by Becton, Dickinson and Company

GenCell Biosystems acquired by Becton, Dickinson and Company

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications. [More]
MiMedx announces record revenue results for Q3 2014, issues updated guidance

MiMedx announces record revenue results for Q3 2014, issues updated guidance

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance. [More]

OBN, ABPI sign MoU to build a better public profile

13 October 2014, London and Oxford: The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK's emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU). [More]

United Life Sciences partnership formed and Life Sciences Manifesto 2015 – 2020 published

Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow’s members in the north of the UK and the wider UK sector. [More]
Imricor enters into license agreement with Sorin Group to develop MRI compatible technology

Imricor enters into license agreement with Sorin Group to develop MRI compatible technology

Imricor Medical Systems, Inc. today announced that it has entered into a license agreement with Sorin Group to develop magnetic resonance imaging (MRI) compatible leads for use with Sorin implantable cardiac rhythm management devices. [More]
New Colombia creates joint venture to produce cannabis and hemp based medicinal products

New Colombia creates joint venture to produce cannabis and hemp based medicinal products

New Colombia Resources, Inc., a U.S. company with coal and other resource assets in Colombia, is pleased to announce they have formed a joint venture to produce cannabis and hemp based medicinal products in Colombia in association with an indigenous community in Colombia. [More]
GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal. [More]
Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

Astute Medical, Inc. and CRG today announced that Astute recently achieved a milestone under the terms of its existing term loan agreement with CRG. Under the term loan agreement, CRG will provide up to $30 million to support the commercialization of the NephroCheck Test System. [More]
Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). [More]
Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. [More]
Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments. [More]